Deciphering Antidepressant Research January 1, 2007 From The Carlat Psychiatry Report Issue Links: Learning Objectives | Editorial Information | PDF of Issue I know that you published a famous meta-analysis several years ago in which you compared the remission rates of patients on venlafaxine with SSRIs and placebo. Can you remind us of what that study showed?Read More
General PsychiatryKarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change EverythingRead More
General PsychiatryPsychopharm Secrets: What Patients Won’t Tell YouHow to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.Listen now
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered PractitionersMay 24, 2024
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
